import type { HybridReportData } from '~/home/(user)/reports/_lib/types/hybrid-report-display.types';

/**
 * Food Tech Hybrid Report Example Data
 * Precision Fermentation Scale-Up
 */
export const FOODTECH_HYBRID_REPORT: HybridReportData = {
  title:
    'Precision Fermentation Scale-Up: Achieving $2-5/kg Protein at 50,000L Through Paradigm Shift from Batch to Continuous Processing',
  brief:
    'Precision fermentation proteins (whey, collagen, heme) achieve cost parity at >100,000L scale, but most facilities are 10,000-50,000L. Scaling up hits oxygen transfer limits, contamination risk, and 40-60% of batches fail to meet spec. Need pathway to $2-5/kg protein cost at 50,000L scale with >90% batch success rate.',

  executive_summary: {
    narrative_lead:
      'Pharma biologics solved this exact problem 15 years ago by abandoning batch processing entirely. Continuous perfusion with cell retention achieves 10x volumetric productivity with >95% operational uptime—eliminating \'batch failures\' by eliminating batches. The precision fermentation industry inherited batch processing from pharma without questioning whether it applies; the answer is that it doesn\'t. A 10,000L perfusion system can match 100,000L batch output while transforming the 40-60% failure rate into a steady-state control problem.',
    primary_recommendation:
      'Deploy continuous perfusion fermentation with ATF cell retention, targeting 10,000-20,000L working volume to match current 50,000L batch output. Investment of $2-5M over 18-24 months yields 10x volumetric productivity and near-elimination of batch variability. In parallel, optimize conventional approaches (pure O2 sparging, PAT deployment) to improve current operations while perfusion is developed.',
    viability: 'conditionally_viable',
    viability_label: 'Viable with moderate confidence—requires adaptation of pharma perfusion technology for yeast/bacterial systems',
  },

  problem_analysis: {
    whats_wrong: {
      prose:
        'Every second batch fails. At 40-60% failure rate, more resources go to failed batches than successful ones—feedstock, energy, labor, and 72-120 hours of cycle time discarded at harvest when the product doesn\'t meet spec. The oxygen transfer limitation forces lower cell densities, longer cycles, and larger vessels than the biology actually requires. This isn\'t a scaling problem; it\'s a paradigm problem.',
    },
    current_state_of_art: {
      benchmarks: [
        {
          entity: 'Perfect Day (precision fermentation)',
          approach:
            'Fed-batch STR fermentation for whey proteins',
          current_performance:
            'Reported $10-20/kg cost at current scale',
          target_roadmap:
            'Targeting cost parity with dairy at >100,000L scale',
          source: 'Press releases and investor presentations, unverified',
        },
        {
          entity: 'Novozymes/DSM (industrial enzymes)',
          approach: 'Mature fed-batch with decades of strain optimization',
          current_performance:
            '$5-20/kg at 100,000-500,000L scale, >95% batch success',
          target_roadmap:
            'Continuous 1-5% annual improvement through strain optimization',
          source: 'Industry reports and academic literature',
        },
        {
          entity: 'Genentech/Amgen (pharma biologics)',
          approach: 'Continuous perfusion with ATF cell retention',
          current_performance:
            '10-50x volumetric productivity vs batch, >95% uptime, 60+ day campaigns',
          target_roadmap: 'Expanding perfusion to more products',
          source: 'Konstantinov & Cooney (2015), Journal of Pharmaceutical Sciences',
        },
      ],
    },
    what_industry_does_today: [
      {
        approach: 'Fed-batch in stirred-tank reactors with incremental kLa optimization',
        limitation:
          'STRs hit practical kLa ceiling of ~500-600/hr at scale; insufficient for >50g/L cell density',
      },
      {
        approach: 'Pure oxygen sparging to boost dissolved oxygen',
        limitation:
          'Creates oxidative stress, foam issues, and fire safety complexity; often partially implemented, not fully optimized',
      },
      {
        approach: 'Scale-up by building larger vessels (100,000-200,000L)',
        limitation:
          'Larger vessels have worse mass transfer (surface area to volume ratio); $50-100M capital requirement',
      },
      {
        approach: 'Strain engineering for higher expression titers',
        limitation:
          'Diminishing returns on titer improvement; doesn\'t address oxygen limitation or batch variability',
      },
    ],
    why_its_hard: {
      prose:
        'Oxygen mass transfer is governed by OTR = kLa × (C* - CL), where kLa is the volumetric mass transfer coefficient and (C* - CL) is the driving force between saturation and actual dissolved oxygen. At high cell density (>50g/L), oxygen uptake rate (OUR) can exceed 100-200 mmol O2/L/hr. Conventional sparging in large STRs achieves kLa of 200-400/hr with air, yielding maximum OTR of ~50-100 mmol/L/hr—insufficient for high-density aerobic culture. The physics is unforgiving: larger vessels have worse surface-area-to-volume ratios, and bubble coalescence reduces interfacial area. You cannot engineer your way around thermodynamics.',
      governing_equation: {
        equation:
          'OTR = kLa × (C* - CL) ≥ OUR',
        explanation:
          'Oxygen transfer rate must equal or exceed oxygen uptake rate. At high cell density, OUR increases linearly while OTR hits practical ceiling. The gap forces lower cell density, longer cycles, and higher per-kg costs.',
      },
    },
    first_principles_insight: {
      headline:
        'The batch paradigm is the problem, not batch reliability',
      explanation:
        'Industry is trying to make batches more reliable when the answer is to eliminate batches entirely. Continuous perfusion maintains cells at steady-state optimal conditions indefinitely—no lag phase, no stationary phase decline, no batch-to-batch variability. There are no batches to fail. Pharma biologics made this transition 15+ years ago for identical reasons: batch variability was unacceptable for high-value products. Precision fermentation proteins are simpler than antibodies; the technology transfer is straightforward.',
    },
  },

  constraints_and_metrics: {
    hard_constraints: [
      'Must achieve food-grade/regulatory compliance for protein products',
      'Cannot exceed practical vessel pressure ratings without new construction (typically 1-2 bar for existing vessels)',
      'Must maintain protein functionality and folding for target applications',
    ],
    soft_constraints: [
      '50,000L vessel scale (analysis includes alternatives if this is negotiable)',
      'Timeline pressure from investors/market (longer-term solutions may be strategically superior)',
      'Existing equipment and facility layout (retrofit vs greenfield tradeoffs)',
    ],
    assumptions: [
      'Cost target of $2-5/kg is fermentation + primary recovery; DSP adds $3-8/kg additional',
      'Failure modes are mixed: ~20% contamination, ~40% low titer, ~40% protein quality issues',
      'Current kLa is 200-400/hr; need 600-1000/hr for target cell density',
      'Products are secreted proteins (whey, collagen, heme) with different expression challenges',
    ],
    success_metrics: [
      {
        metric: 'Cost per kg protein',
        target: '$3/kg',
        minimum_viable: '$5/kg',
        stretch: '$2/kg',
        unit: 'USD/kg',
      },
      {
        metric: 'Batch/campaign success rate',
        target: '95%',
        minimum_viable: '90%',
        stretch: '>99%',
        unit: '% meeting spec',
      },
      {
        metric: 'Volumetric productivity',
        target: '5 g/L/day',
        minimum_viable: '2 g/L/day',
        stretch: '10 g/L/day',
        unit: 'g protein/L/day',
      },
      {
        metric: 'Cell density achieved',
        target: '75 g/L DCW',
        minimum_viable: '50 g/L DCW',
        stretch: '100 g/L DCW',
        unit: 'g dry cell weight/L',
      },
    ],
  },

  challenge_the_frame: [
    {
      assumption:
        'The 50,000L vessel scale is fixed',
      challenge:
        'If the goal is $2-5/kg protein cost, vessel size is a means, not an end. A 10,000L perfusion system achieving 10x productivity matches 100,000L batch output. The constraint may be self-imposed.',
      implication:
        'If vessel size is negotiable, perfusion at smaller scale may be superior to optimizing larger batch vessels. Capital efficiency improves dramatically.',
    },
    {
      assumption: 'Batch failures are a process engineering problem',
      challenge:
        'Brewing achieves >99% batch success with simpler technology than precision fermentation uses. The difference is strain maturity—centuries vs years of optimization. Process engineering may be compensating for immature strains.',
      implication:
        'If strain robustness is the binding constraint, ALE investment may have higher ROI than process engineering. The enzyme industry\'s patient approach may be the right model.',
    },
    {
      assumption: 'The failure modes are mixed (contamination, titer, quality)',
      challenge:
        'If one failure mode dominates, the solution focus changes dramatically. If 80% of failures are low titer due to oxygen limitation, solving oxygen solves the problem. If 80% are contamination, sterility improvements matter most.',
      implication:
        'Detailed failure mode analysis should precede major investment. The assumed 20/40/40 split may not reflect reality.',
    },
    {
      assumption: 'Food-grade regulatory requirements are similar to pharma',
      challenge:
        'Food ingredients have different regulatory pathways than pharmaceuticals. Continuous processing is already accepted in food manufacturing. The perceived regulatory barriers may be lower than assumed.',
      implication:
        'Regulatory pathway investigation should happen early. If continuous food fermentation has clear precedent, the timeline for perfusion deployment shortens.',
    },
  ],

  innovation_analysis: {
    reframe:
      'Instead of asking \'how do we make batches more reliable at 50,000L,\' we asked \'what if batch processing itself is the wrong paradigm for oxygen-limited protein production?\'',
    domains_searched: [
      'Pharmaceutical biologics manufacturing',
      'Industrial enzyme production',
      'Wastewater treatment',
      'Aquaculture oxygenation',
      'ICI Pruteen historical process',
      'Electrochemistry',
      'Biofilm reactor engineering',
      'Deep-sea biology',
    ],
  },

  execution_track: {
    intro:
      'Solution concepts use proven technologies requiring integration and adaptation, not fundamental invention. These represent the highest-confidence paths to achieving target economics with manageable risk.',
    primary: {
      id: 'sol-primary',
      title:
        'Continuous Perfusion with ATF Cell Retention',
      confidence: 80,
      source_type: 'TRANSFER',
      bottom_line:
        'Convert from batch to continuous perfusion operation using alternating tangential flow (ATF) or tangential flow filtration (TFF) cell retention.',
      expected_improvement: '10x volumetric productivity, near-elimination of batch failures',
      timeline: '18-24 months to commercial deployment',
      investment: '$2-5M',
      the_insight: {
        what: 'Batch processing traverses multiple metabolic states where small perturbations compound into batch failures. Steady-state continuous operation maintains cells at optimal conditions indefinitely, eliminating batch-to-batch variability at its source.',
        where_we_found_it: {
          domain: 'Pharmaceutical biologics manufacturing',
          how_they_use_it:
            'Genentech, Amgen, and Roche converted batch to perfusion 2005-2015 for monoclonal antibody production, achieving 10-50x volumetric productivity with >95% uptime',
          why_it_transfers:
            'Precision fermentation proteins are simpler than antibodies. The cell retention challenge (yeast/bacteria vs mammalian cells) requires adaptation but not invention.',
        },
        why_industry_missed_it:
          'Precision fermentation inherited batch processing from pharma without questioning whether it applies. Perfusion is perceived as \'complex\' despite batch failure management being more complex. The startup \'fail fast\' culture accepts batch failures rather than investing in batch elimination.',
      },
      what_it_is:
        'Convert from batch to continuous perfusion operation using alternating tangential flow (ATF) or tangential flow filtration (TFF) cell retention. Cells are maintained at steady-state high density (50-100g/L DCW) while spent medium containing secreted product is continuously removed and fresh medium is continuously added. The system reaches steady-state within 5-10 days and then operates indefinitely at constant productivity.\n\nThe cell retention device (hollow fiber membrane) keeps cells in the bioreactor while allowing product-containing permeate to flow through. Dilution rate is controlled to match specific growth rate, maintaining cells in optimal physiological state. Dissolved oxygen is maintained through continuous feed of fresh, oxygenated medium combined with conventional or enhanced sparging.\n\nCritically, this eliminates the concept of \'batch failure\' entirely. There are no batches—only a continuous steady-state that either meets spec or doesn\'t. Deviations are detected in hours and corrected, not discovered at harvest after 72-120 hours of wasted resources.',
      why_it_works:
        'The physics is straightforward: steady-state operation at controlled dilution rate maintains cells at constant specific growth rate, avoiding the lag phase (low productivity), late exponential phase (oxygen limitation), and stationary phase (product degradation, cell death) that characterize batch fermentation. Product is harvested continuously before it can accumulate to inhibitory concentrations or be degraded by proteases. Oxygen demand is constant and predictable rather than peaking during exponential phase. The 10x volumetric productivity means a 10,000L perfusion system matches 100,000L batch output—achieving the economics of larger scale without the capital investment.',
      why_it_might_fail: [
        'Cell retention systems optimized for mammalian cells may not work efficiently for smaller yeast/bacteria',
        '18-24 month perfusion development timeline may exceed organizational patience or funding runway',
        'Genetic drift over long perfusion campaigns may reduce productivity',
      ],
      validation_gates: [
        {
          week: 'Month 1-3',
          test: 'Bench-scale perfusion proof-of-concept with production strain',
          method:
            '2L perfusion system with ATF or TFF cell retention; operation for 30+ days at steady-state',
          success_criteria:
            'Achieve steady-state at >50g/L DCW for >30 days with product titer within 80% of batch peak; cell retention >95%',
          cost: '$150-300K (equipment rental/purchase + 3 months operation + analysis)',
          decision_point:
            'If cell retention <90% or steady-state cell density <30g/L, troubleshoot membrane selection and operating parameters. If issues persist, evaluate alternative cell retention technologies or pivot to enhanced batch.',
        },
      ],
    },
    supporting_concepts: [
      {
        id: 'sol-support-1',
        title: 'Intensive PAT Deployment with Model Predictive Control',
        relationship: 'COMPLEMENTARY',
        one_liner:
          'Requires 20-50 batches of training data before models are accurate; during learning period, failure rate may not improve',
        confidence: 75,
        what_it_is:
          'Deploy comprehensive real-time monitoring (Raman spectroscopy for metabolites, NIR for biomass, soft sensors for product) integrated with model predictive control. Detect deviations within 2-4 hours and correct mid-batch rather than discovering failure at harvest. This converts the binary pass/fail outcome at 72-120 hours into continuous trajectory management with intervention capability.\n\nThe system uses multivariate sensors to continuously measure metabolite profiles, dissolved oxygen gradients, and cell physiological state. Machine learning models trained on historical batch data predict trajectory deviations 4-8 hours before they become irrecoverable. MPC adjusts feed rates, temperature, pH, and aeration in real-time.',
        why_it_works:
          'Real-time measurement of process state enables closed-loop control that maintains optimal conditions despite disturbances. Failed batches detected early enough to abort and restart save 60-80% of batch time versus discovering failure at harvest.',
        when_to_use_instead:
          'Deploy immediately in parallel with perfusion development. PAT improves current batch operations while perfusion is being developed. Also valuable for perfusion operation—continuous monitoring is even more critical for steady-state control.',
      },
      {
        id: 'sol-support-2',
        title: 'Pure Oxygen Sparging Optimization with Microbubble Enhancement',
        relationship: 'FALLBACK',
        one_liner:
          'Microbubble stability in protein-rich fermentation media is poorly characterized; coalescence may reduce effectiveness',
        confidence: 65,
        what_it_is:
          'Systematically optimize pure O2 sparging combined with microbubble generators to maximize kLa within existing vessels. Pure oxygen provides 5x higher partial pressure than air; microbubbles provide 5-10x higher interfacial area than conventional sparging. Combined, these could achieve 3-5x OTR improvement without vessel replacement.\n\nMicrobubble generators (venturi-based or mechanical) produce 10-100 μm bubbles versus conventional 2-5 mm bubbles. Since interfacial area scales with 1/diameter, microbubbles achieve dramatically higher kLa per volume of gas.',
        why_it_works:
          'Henry\'s Law (pure O2 increases C* from ~8 to ~40 mg/L) combined with microbubble physics (100x smaller bubbles = 100x more surface area) provides multiplicative improvement in oxygen transfer capacity.',
        when_to_use_instead:
          'If perfusion development encounters fundamental barriers (cell retention failure, regulatory obstacles), enhanced batch with PAT + microbubbles + pure O2 provides fallback path to improved economics within existing paradigm. Also valuable as interim improvement while perfusion is developed.',
      },
    ],
  },

  innovation_portfolio: {
    intro:
      'Higher-risk explorations with breakthrough potential. Innovation concepts offer higher ceilings with higher uncertainty. These represent parallel bets on breakthrough outcomes that could fundamentally change precision fermentation economics if successful.',
    recommended_innovation: {
      id: 'innov-recommended',
      title: 'Pressurized Continuous Fermentation (ICI Pruteen Revival)',
      confidence: 65,
      innovation_type: 'CROSS_DOMAIN',
      source_domain: 'ICI Pruteen process (1970s-80s)',
      the_insight: {
        what: 'Henry\'s Law provides 3-5x oxygen solubility at 3-5 bar—fundamental thermodynamics that cannot be circumvented but can be exploited',
        where_we_found_it: {
          domain: 'ICI Pruteen single-cell protein production (1970s-80s)',
          how_they_use_it:
            'ICI achieved 50,000+ tonnes/year bacterial protein production at costs of $0.30-0.50/kg using pressurized continuous fermentation',
          why_it_transfers:
            'At 3 bar with pure oxygen, oxygen saturation concentration increases from ~40 mg/L to ~120 mg/L—a 3x increase in the thermodynamic driving force for mass transfer.',
        },
        why_industry_missed_it:
          'The ICI Pruteen process was abandoned due to high energy costs from methanol substrate, not process failure. The fermentation technology itself was proven at massive scale. Modern precision fermentation uses cheaper substrates but hasn\'t revisited the pressure engineering.',
      },
      what_it_is:
        'Combine continuous perfusion with pressurized operation at 3-5 bar to exploit Henry\'s Law for 3-5x higher oxygen solubility. This is the approach ICI used for the Pruteen process in the 1970s-80s, achieving 50,000+ tonnes/year bacterial protein production at costs of $0.30-0.50/kg.\n\nAt 3 bar with pure oxygen, oxygen saturation concentration increases from ~40 mg/L to ~120 mg/L—a 3x increase in the thermodynamic driving force for mass transfer. This is additive with kLa improvements: if kLa is 400/hr and C* is 120 mg/L (versus 40 mg/L at 1 bar), OTR increases 3x without any change to mass transfer equipment.\n\nThe vessel requires pressure rating (standard in chemical processing, 20-40% cost premium) but no fundamental redesign. Combined with continuous operation and modern control systems, this could achieve productivity levels that current precision fermentation hasn\'t approached.',
      why_it_works:
        'Henry\'s Law is fundamental thermodynamics: C* = H × pO2. At 3 bar, oxygen solubility is 3x atmospheric. This increases the \'ceiling\' that mass transfer approaches, enabling higher cell density and productivity without improving kLa. The cells don\'t \'know\' the pressure is elevated—each oxygen molecule in solution has the same activity as at atmospheric pressure. Most production organisms tolerate 5-10 bar without significant growth inhibition.',
      breakthrough_potential: {
        if_it_works:
          'Achieves commodity-scale protein economics ($1-3/kg) at 50,000L scale',
        estimated_improvement:
          '3-5x OTR capacity from pressure alone; combined with perfusion, potentially 30-50x productivity versus current batch',
        industry_impact:
          'Would enable precision fermentation cost parity with commodity proteins, opening mass-market food ingredient applications',
      },
      validation_path: {
        gating_question:
          'Can production strain maintain productivity and stability at 3-5 bar pressure?',
        first_test:
          'Pressurized shake flask or mini-bioreactor studies at 2-5 bar; measure growth rate, titer, and product quality versus atmospheric control',
        cost: '$50-100K (pressure-rated equipment + 3 months operation + analysis)',
        timeline: '3-4 months',
        go_no_go:
          'GO if growth rate and titer within 80% of atmospheric control at 3 bar. NO-GO if significant growth inhibition or protein quality issues.',
      },
      risks: {
        physics_risks: [
          'Pressure vessel capital cost may exceed budget for existing facilities',
          'Some organisms may show unexpected pressure sensitivity',
        ],
        implementation_challenges: [
          'Pressure-rated vessel procurement and installation',
          'Safety protocols for pressurized fermentation',
        ],
        mitigation: [
          'Start with smaller pressure-rated vessel for proof-of-concept',
          'Partner with chemical engineering firms experienced in pressurized bioprocessing',
          'Implement standard pressure vessel safety protocols',
        ],
      },
    },
    parallel_investigations: [
      {
        id: 'innov-parallel-1',
        title:
          'Metabolic Engineering for Reduced Oxygen Demand (VHb Expression)',
        confidence: 70,
        innovation_type: 'OPTIMIZATION',
        source_domain: 'Bacterial hemoglobin research',
        one_liner:
          'Engineer production strains to express Vitreoscilla hemoglobin (VHb), which provides intracellular oxygen buffering and delivery to cytochromes',
        the_insight: {
          what: 'VHb binds oxygen at very low concentrations (Kd ~10 nM) and delivers it directly to respiratory enzymes, improving oxygen utilization efficiency by 20-40%',
          where_we_found_it: {
            domain: 'Bacterial hemoglobin research and industrial strain engineering',
            how_they_use_it:
              'VHb expression has been shown to improve growth and product yields in oxygen-limited conditions across multiple organisms',
            why_it_transfers:
              'This attacks the demand side of the oxygen equation (OUR) rather than the supply side (OTR), providing an orthogonal improvement pathway',
          },
          why_industry_missed_it:
            'Focus has been on supply-side solutions (better aeration, larger vessels). Demand-side reduction through metabolic engineering is underexplored in precision fermentation.',
        },
        ceiling:
          '20-40% reduction in oxygen demand, enabling higher cell density in existing equipment',
        key_uncertainty:
          'VHb expression adds metabolic burden that may reduce product titer; must optimize expression level to balance benefits',
        when_to_elevate:
          'If supply-side solutions (perfusion, pressure, microbubbles) prove insufficient or too capital-intensive, demand-side reduction becomes primary strategy',
        validation_approach: {
          test: 'Express VHb in production strain; compare growth and titer under oxygen-limited conditions versus parent strain',
          cost: '$50-100K',
          timeline: '3-4 months',
          go_no_go:
            'GO if oxygen demand reduced >20% with <10% titer reduction. NO-GO if titer drops >20% or no measurable oxygen demand improvement.',
        },
      },
      {
        id: 'innov-parallel-2',
        title: 'Adaptive Laboratory Evolution for Strain Robustness',
        confidence: 75,
        innovation_type: 'OPTIMIZATION',
        source_domain: 'Industrial enzyme strain development',
        one_liner:
          'Launch systematic adaptive laboratory evolution (ALE) under production-relevant stress conditions to develop strains with brewing-like robustness',
        the_insight: {
          what: 'Subject production strains to 100-500 generations of selection under stressful conditions (oxygen limitation, high density, late-batch metabolite accumulation); evolved strains accumulate mutations conferring stress tolerance',
          where_we_found_it: {
            domain: 'Industrial enzyme and brewing industry strain development',
            how_they_use_it:
              'Brewing achieves >99% batch success with strains evolved over centuries. Enzyme industry uses systematic ALE to develop robust production strains.',
            why_it_transfers:
              'The 40-60% failure rate may reflect strain immaturity rather than process limitations. ALE addresses the root cause.',
          },
          why_industry_missed_it:
            'Precision fermentation startups focus on rapid titer improvement rather than patient strain robustness development. The \'fail fast\' culture doesn\'t align with ALE timelines.',
        },
        ceiling:
          'Brewing-like robustness (>99% batch success) without major process changes',
        key_uncertainty:
          'Maintaining expression level while selecting for stress tolerance requires careful dual-selection protocols',
        when_to_elevate:
          'If process engineering solutions plateau and batch failures persist, strain robustness becomes the binding constraint',
        validation_approach: {
          test: 'Run parallel ALE campaigns under oxygen limitation, high density, and metabolite stress; screen evolved strains for batch success rate improvement',
          cost: '$100-200K',
          timeline: '6-12 months',
          go_no_go:
            'GO if evolved strains show >30% improvement in batch success rate with <10% titer reduction. NO-GO if no robustness improvement or unacceptable titer loss.',
        },
      },
    ],
    frontier_watch: [
      {
        id: 'frontier-1',
        title: 'In-Situ Electrochemical Oxygen Generation',
        innovation_type: 'PARADIGM',
        trl_estimate: 3,
        one_liner:
          'Eliminates the fundamental kLa limitation—oxygen appears at the molecular level exactly where it\'s produced',
        why_interesting:
          'Could enable arbitrarily high oxygen delivery rates limited only by electrode area and power supply. Hydrogen co-product could be captured for energy recovery.',
        why_not_now:
          'Electrode fouling in protein-rich fermentation media is the critical uncertainty. Early attempts (1980s-90s) failed due to rapid fouling. Modern electrodes are more resistant but validation in fermentation media is needed. Local pH effects at electrodes could damage cells.',
        trigger_to_revisit:
          'Publication demonstrating >1000 hours electrode operation in fermentation media without significant fouling; or commercial announcement of bioprocess-specific electrochemical oxygenation system',
        who_to_monitor:
          'Nel Hydrogen (electrolyzer technology), ITM Power (PEM electrolysis), Academic groups at TU Delft and MIT working on bioelectrochemical systems, Electrochemistry conferences (ECS meetings)',
        earliest_viability: '3-5 years',
        competitive_activity:
          'Limited commercial activity in bioprocess application. Academic research ongoing but no breakthrough yet.',
      },
      {
        id: 'frontier-2',
        title: 'Biofilm Fermentation for Secreted Proteins',
        innovation_type: 'PARADIGM',
        trl_estimate: 2,
        one_liner:
          'Biofilm reactors require minimal mixing energy and achieve very high oxygen transfer efficiency',
        why_interesting:
          'If protein secretion from biofilms is efficient, this could enable 10x productivity with 50-80% energy reduction.',
        why_not_now:
          'Critical uncertainty: can secreted proteins diffuse out of biofilms efficiently, or will they be trapped in the extracellular matrix? This fundamental question is unanswered. Biofilm thickness control is also challenging.',
        trigger_to_revisit:
          'Publication demonstrating efficient secreted protein recovery from thin biofilms with >50% of suspended culture productivity; or proof-of-concept for biofilm thickness control in protein production',
        who_to_monitor:
          'OxyMem and Fluence (commercial MABR systems), Academic groups at University of Notre Dame and Delft working on biofilm protein production, Vinegar production industry (existing biofilm fermentation)',
        earliest_viability: '4-6 years',
        competitive_activity:
          'Academic research active. No commercial precision fermentation applications yet.',
      },
    ],
  },

  risks_and_watchouts: [
    {
      category: 'Technical',
      risk: 'Cell retention systems optimized for mammalian cells may not work efficiently for smaller yeast/bacteria',
      severity: 'high',
      mitigation:
        'Pilot testing with appropriate membranes; engage suppliers with microbial experience (Repligen has microbial-specific products); potentially custom membrane development',
    },
    {
      category: 'Technical',
      risk: 'Microbubble coalescence in protein-rich media may reduce effectiveness below wastewater benchmarks',
      severity: 'medium',
      mitigation:
        'Pilot testing in actual fermentation media before full-scale commitment; characterize coalescence rates under process conditions',
    },
    {
      category: 'Market',
      risk: 'Competitor achieves cost parity through different approach (larger scale, different geography, strain breakthrough)',
      severity: 'medium',
      mitigation:
        'Pursue multiple parallel paths; maintain flexibility to pivot; focus on approaches that provide structural advantage (perfusion productivity, pressure physics)',
    },
    {
      category: 'Regulatory',
      risk: 'Continuous food ingredient production may face unexpected regulatory hurdles',
      severity: 'medium',
      mitigation:
        'Engage FDA/relevant regulators early; document continuous processing precedents in food manufacturing; build regulatory strategy in parallel with technical development',
    },
    {
      category: 'Resource',
      risk: '18-24 month perfusion development timeline may exceed organizational patience or funding runway',
      severity: 'high',
      mitigation:
        'Pursue quick wins (PAT, O2 optimization) in parallel to show progress; structure development with clear milestones and decision gates; consider partnership with pharma company experienced in perfusion',
    },
    {
      category: 'Technical',
      risk: 'Genetic drift over long perfusion campaigns may reduce productivity',
      severity: 'low',
      mitigation:
        'Regular strain banking; productivity monitoring; restart protocols; strain stability is manageable with proper procedures',
    },
  ],

  self_critique: {
    confidence_level: 'medium',
    overall_confidence: 'medium',
    confidence_rationale:
      'High confidence in the physics and the pharma precedent; medium confidence in the adaptation to yeast/bacteria and food-grade requirements',
    what_we_might_be_wrong_about: [
      'Cell retention efficiency for yeast/bacteria may be fundamentally lower than mammalian cells, requiring more development than estimated',
      'Continuous DSP for food proteins may be less mature than assumed, adding timeline and cost',
      'The 40-60% batch failure rate may have causes we haven\'t identified that persist even with perfusion',
      'Organizational/cultural resistance to paradigm shift may be stronger than technical barriers',
    ],
    unexplored_directions: [
      'Co-culture systems that reduce oxygen demand through metabolic division of labor—didn\'t pursue due to complexity and regulatory uncertainty',
      'Solid-state or semi-solid fermentation for some protein types—may be relevant for specific products but not general solution',
      'Alternative feedstocks (CO2, methane) that change the economics entirely—outside scope but worth monitoring',
    ],
    validation_gaps: [
      {
        concern: 'Cell retention efficiency for yeast/bacteria may be fundamentally lower than mammalian cells',
        status: 'ADDRESSED',
        rationale:
          'First validation step specifically tests cell retention with production strain; go/no-go criteria defined',
      },
      {
        concern: 'Continuous DSP for food proteins may be less mature than assumed',
        status: 'EXTENDED_NEEDED',
        rationale:
          'Should add parallel DSP development workstream; current validation focuses on fermentation only',
      },
      {
        concern: 'The 40-60% batch failure rate may have causes we haven\'t identified',
        status: 'EXTENDED_NEEDED',
        rationale:
          'Recommend detailed failure mode analysis before major investment; current assumption of 20/40/40 split is unvalidated',
      },
      {
        concern: 'Organizational resistance to paradigm shift',
        status: 'ACCEPTED_RISK',
        rationale:
          'Technical analysis cannot address organizational culture; this is a leadership challenge, not an engineering challenge',
      },
    ],
  },

  what_id_actually_do:
    "If this were my project, I'd start three workstreams tomorrow.\n\nFirst, I'd call Repligen and Sartorius and get a bench-scale perfusion system on order. This is the transformative bet—everything else is incremental. The pharma industry proved this works; we just need to adapt it. I'd budget $300K and 6 months for proof-of-concept. If cell retention works for our strain, we're on the path to 10x productivity. If it doesn't, we learn that fast and cheap.\n\nSecond, I'd deploy PAT on our existing batches immediately. Raman spectroscopy and soft sensors are commercial products. We're probably leaving 30-50% batch success improvement on the table by not monitoring properly. This pays for itself in avoided failed batches while we develop perfusion. Budget $500K-1M over 12 months.\n\nThird, I'd dig into the ICI Pruteen literature—patents, publications, and if possible, track down retired engineers who worked on it. They solved these problems 40 years ago at larger scale than we're attempting. The knowledge exists; we just need to find it. This is a $50K research project that could save millions in development.\n\nThe one thing I would NOT do is build a bigger vessel. That's the industry's default answer, and it's wrong. Larger vessels have worse mass transfer, not better. The answer is higher productivity per liter, not more liters.",

  follow_up_prompts: [
    'Design a bench-scale perfusion pilot study for our production strain',
    'Help me build a business case comparing perfusion at 10,000L versus batch at 50,000L',
    'What PAT sensors should we deploy first, and what will they cost?',
    'Find and summarize the ICI Pruteen literature—patents, publications, and key learnings',
    'Create a failure mode analysis framework for our current batch operations',
  ],
};
